European Journal of Haematology

Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine

Transplantation and Cellular Therapy

Risk stratification using DIPSS and splenomegaly in myelofibrosis treated with pre-transplant JAK inhibitors

Nature Communications

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

American Journal of Hematology

Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT

Journal of Hematology

Efficacy and safety of momelotinib in myelofibrosis: A systematic review and meta-analysis with a focus on anemia outcomes

Journal of Inflammation Research

Prognostic implications of red blood cell distribution width to albumin ratio in myelofibrosis: A 10 year multicenter and retrospective study

Clinical Lymphoma, Myeloma & Leukemia

Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

International Journal of Hematology

Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

Blood

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

Acta Haematologica

Impact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP studyImpact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP study